Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has shared an announcement.
EBR Systems, Inc. announced significant progress in Q3 2025, securing CMS approval for both NTAP and TPT reimbursement for its WiSE CRT System, effective October 2025. This approval establishes a comprehensive Medicare reimbursement pathway, enhancing the system’s adoption in both inpatient and outpatient settings. The company reported a 201% increase in revenue from Q2 to Q3 2025, driven by a tripling of case volumes and successful pilot launches. EBR also advanced its Limited Market Release preparations, signing additional purchasing agreements and training physicians, which aligns with the commencement of U.S. Medicare reimbursement programs. These developments are expected to accelerate the adoption and operational processes of the WiSE CRT System, positioning EBR for further growth.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
EBR Systems, Inc., based in Sunnyvale, California, is a developer of the world’s only wireless cardiac pacing device for heart failure. The company focuses on innovative solutions in the medical device industry, specifically targeting cardiac resynchronization therapy (CRT) with its WiSE CRT System.
Average Trading Volume: 645,054
Technical Sentiment Signal: Sell
Current Market Cap: A$532.7M
Learn more about EBR stock on TipRanks’ Stock Analysis page.